Banner Art
Text  Increase Text SizeDecrease Text Size

Pharmacy and Therapeutics (P&T) Committee


P&T Committee Information

The Pharmacy and Therapeutics (P&T) Committee is an advisory board established pursuant to Executive Order D004-07. The committee performs clinical reviews of drug classes and makes recommendations which help the Department develop and manage the Medicaid Preferred Drug List (PDL).

The P&T Committee is required to consider clinical criteria such as drug safety and efficacy when making its recommendations. The committee also considers public comments and testimony related to the drug classes being reviewed or other PDL-related agenda items.

The P&T Committee consists of 7 physicians, 4 pharmacists and 2 client representatives, who are appointed by the Department's Executive Director. Review the Policies and Procedures Manual for more information on the committee's membership, duties and policies.


Current P&T Committee Members 


January 2013 - December 2014 Term January 2014 - December 2015 Term
Kimberly Nordstrom, M.D., J.D. (Vice-Chairperson) Patricia M. Lanius, R.Ph
Leslie Moldauer, M.D., MBA Michael F. McGuire, MPA
David Fox, M.D. Katy Trinkley, PharmD.
Shilpa Kinikar, Pharm.D., BCPS (Chairperson) Lynn Parry, M.D.
Irene Girgis, Pharm.D. Jennifer S. Hyer, M.D.
  Neil Stafford, M.D.
  Roy J. Durbin Jr., M. D.


Presenting Testimony

Interested parties that would like to present testimony to the P&T Committee may sign up on the day of a meeting; however, the Department encourages giving advanced notice by contacting Swaniee Grubb, the committee coordinator, at 303-866-3614 or

Potential P&T Committee Members 

There is currently one openings on the P & T Committee for a client representative.

If you are interested in serving or know someone who would be qualified, please submit a CV along with a completed Conflict of Interest form to Swaniee Grubb, 1570 Grant St., Denver, CO 80203, or fax to 303-866-3590 Attn: Swaniee Grubb.